MESOBLAST LTD
Business
Mesoblast Limited is a commercial-stage biotechnology company developing allogeneic cellular medicines based on mesenchymal lineage cell technology for treating severe inflammatory conditions. The company's first FDA-approved product, Ryoncil® (remestemcel-L-rknd), launched in the U.S. in March 2025 for steroid-refractory acute graft versus host disease in pediatric patients; additional candidates in late-stage development target chronic heart failure, chronic low back pain, and inflammatory bowel disease. Mesoblast markets through its own commercial organization focused on U.S. transplant centers and partners with licensees in Japan and Europe for commercialization of MSC-based therapies.
Summary from 20-F filed 2025-08-29
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | — |
| Total assets | $784.68M |
| Total liabilities | $187.24M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is MESOBLAST LTD's CIK number?
MESOBLAST LTD's SEC CIK number is 0001345099 (1345099). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find MESOBLAST LTD's SEC filings?
All of MESOBLAST LTD's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.